Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30602600 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL7607595 | 0.98 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL7600213 | 0.92 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL29460273 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL30522589 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL18415475 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL21065524 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL4743413 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL16517129 | 0.85 | SMN1; SMN2 (0.83) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL10402199 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | claimed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | claimed |
| US-9511073-B2 | Aromatic amides and uses thereof | TAXIS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | claimed |
| EP-2699557-A1 | AROMATIC AMIDES AND USES THEREOF | Biota Scientific Management Pty Ltd (AU) | 2014-02-26 | — | — | EP | claimed |
| WO-2012142671-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-10-26 | — | — | WO | claimed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | claimed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| JP-2007509075-A | — | — | 2007-04-12 | — | — | JP | claimed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | claimed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | claimed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1266900-A1 | Carbamates of rapamycin | Wyeth (US) | 2002-12-18 | — | — | EP | claimed |
| CN-1036591-C | Carbamates of rapamycin | AMERICAN HOME PROD (US) | 1997-12-03 | — | — | CN | claimed |
| CN-1091135-A | The carbamate of Wyeth-Ayerst Laboratories | AMERICAN HOME PROD (US) | 1994-08-24 | — | — | CN | claimed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | claimed |
| US-5302584-A | Immunosuppressants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | claimed |
| US-12565505-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| US-11878986-B2 | Poly heterocyclic conjugates and their pharmaceutical uses | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-01-23 | — | — | US | disclosed |
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4168005-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | National Health Research Institutes (TW) | 2023-04-26 | — | — | EP | disclosed |
| US-20230080483-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| EP-3946604-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | The Scripps Research Institute (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210403483-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-12-30 | — | — | US | disclosed |
| WO-2021262628-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-12-30 | — | — | WO | disclosed |
| CN-109053742-B | Novel tricyclic compounds | ABBVIE 公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | US | disclosed |
| WO-2020205683-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| CN-109053742-A | New tricyclic compound | ABBVIE 公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108774237-A | New tricyclic compound | ABBVIE 公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-104370909-B | Tricyclic compound | ABBVIE 公司 | 2018-09-11 | — | — | CN | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-3266786-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-107531693-A | Novel 5 or 8-substituted imidazo [1, 5-a ] pyridines as inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 百济神州有限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | disclosed |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015179697-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| CN-104370909-A | Novel tricyclic compounds | ABBOTT LAB | 2015-02-25 | — | — | CN | disclosed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| CN-102711476-B | Novel tricyclic compounds | ABBVIE LAB | 2014-12-03 | — | — | CN | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| EP-2506716-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-102711476-A | Novel tricyclic compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| CN-101472925-B | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG | 2012-06-13 | — | — | CN | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-1704148-B1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON INC (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-7803811-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-09-28 | — | — | US | disclosed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| CN-101472925-A | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-1778231-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | US | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| CN-101115715-A | Pyrrolidine derivatives for the treatment of diseases associated with renin activity | NOVARTIS AG (CH) | 2008-01-30 | — | — | CN | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1778231-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006020415-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1266900-A1 | Carbamates of rapamycin | Wyeth (US) | 2002-12-18 | — | — | EP | disclosed |
| CN-1036591-C | Carbamates of rapamycin | AMERICAN HOME PROD (US) | 1997-12-03 | — | — | CN | disclosed |
| US-5411967-A | Antiinflammatory, immunosuppressant, antitumor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| CN-1091135-A | The carbamate of Wyeth-Ayerst Laboratories | AMERICAN HOME PROD (US) | 1994-08-24 | — | — | CN | disclosed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | disclosed |
| US-5302584-A | Immunosuppressants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
| EP-0238202-B1 | GLYCEROL DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1993-04-28 | — | — | EP | disclosed |
| CN-1069025-A | The aryl of platelet activating factor, acid amides, imide and carbamate pyridine antagonists | AMERICAN CYANAMID CO (US) | 1993-02-17 | — | — | CN | disclosed |
| EP-0391179-A2 | Peptide derivatives of amino acids having a renin-inhibiting effect | F. HOFFMANN-LA ROCHE AG (CH) | 1990-10-10 | — | — | EP | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0238202-A2 | Glycerol derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
| US-4426523-A | Preparation of 1-amino-1,3,5-triazine-2,4(1H, 3H)-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-17 | — | — | US | disclosed |
| US-4426523-A | Preparation of 1-amino-1,3,5-triazine-2,4(1H, 3H)-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (31 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | FGFR3, FGFR1, NTRK3 | SMN1; SMN2 3745/4885NPC1 2040/4885RAB9A 1814/4885 |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | SMN1; SMN2 388/4885NPC1 1326/4885RAB9A 4678/4885 |
| US-20230080483-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | SMN1; SMN2 2851/4885NPC1 1541/4885RAB9A 959/4885 |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | SMN1; SMN2 3262/4885NPC1 2332/4885RAB9A 3678/4885 |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | SMN1; SMN2 2748/4885NPC1 4017/4885RAB9A 287/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885NPC1 154/4885RAB9A 2007/4885 |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | SMN1; SMN2 2026/4885NPC1 132/4885RAB9A 2196/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | SMN1; SMN2 2851/4885NPC1 1541/4885RAB9A 959/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885NPC1 154/4885RAB9A 2007/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | SMN1; SMN2 2026/4885NPC1 132/4885RAB9A 2196/4885 |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ELANE, MMP8, NISCH | SMN1; SMN2 4118/4885NPC1 1505/4885RAB9A 3841/4885 |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | TTR, MAP1LC3B, SAAL1 | SMN1; SMN2 894/4885NPC1 2877/4885RAB9A 3384/4885 |
| US-20210403483-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GAA, UGT2B7 | SMN1; SMN2 687/4885NPC1 786/4885RAB9A 1266/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | SMN1; SMN2 3677/4885NPC1 2639/4885RAB9A 667/4885 |
| US-20080096861-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | SMN1; SMN2 4801/4885NPC1 243/4885RAB9A 1478/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | SMN1; SMN2 2851/4885NPC1 1541/4885RAB9A 959/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | SMN1; SMN2 4463/4885NPC1 2775/4885RAB9A 2818/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | SMN1; SMN2 2947/4885NPC1 223/4885RAB9A 1728/4885 |
| US-12565505-B2 | mTORC modulators and uses thereof | RICTOR, MTOR, RPTOR | SMN1; SMN2 2076/4885NPC1 115/4885RAB9A 543/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | SMN1; SMN2 3957/4885NPC1 2194/4885RAB9A 748/4885 |
| US-11878986-B2 | Poly heterocyclic conjugates and their pharmaceutical uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GAA, UGT2B7 | SMN1; SMN2 687/4885NPC1 786/4885RAB9A 1266/4885 |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | SMN1; SMN2 2947/4885NPC1 223/4885RAB9A 1728/4885 |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | FGF2, FGF1, FGFR1 | SMN1; SMN2 4602/4885NPC1 2760/4885RAB9A 1514/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | SMN1; SMN2 388/4885NPC1 1326/4885RAB9A 4678/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | SMN1; SMN2 2947/4885NPC1 223/4885RAB9A 1728/4885 |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | SMN1; SMN2 2947/4885NPC1 223/4885RAB9A 1728/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | SMN1; SMN2 4055/4885NPC1 2645/4885RAB9A 2400/4885 |
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | GOT2, ABAT, OAT | SMN1; SMN2 182/4885NPC1 628/4885RAB9A 2880/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | SMN1; SMN2 4463/4885NPC1 2775/4885RAB9A 2818/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | SMN1; SMN2 894/4885NPC1 2877/4885RAB9A 3384/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885NPC1 154/4885RAB9A 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.